ASIRI HOSPITAL HOLDINGS PLC

PROVISIONAL ACCOUNTS FOR THE PERIOD ENDED
30th September 2026

Asiri Hospital Holdings PLC and Its Subsidiaries

STATEMENT OF PROFIT OR LOSS

For the Period Ended 30 September 2026

	GROUP		COMPANY	
	30-Sep-26	**30-Sep-25**	**30-Sep-26**	**30-Sep-25**
	Rs.	**Rs.**	**Rs.**	**Rs.**
	Un-audited	**Un-audited**	**Un-audited**	**Un-audited**
Revenue	**20,160,818,528**	17,240,460,935	**9,006,857,848**	7,848,994,841
Cost of Services	**(9,740,196,102)**	(8,591,094,824)	**(4,031,110,974)**	(3,636,863,554)
Gross Profit	**10,420,622,426**	8,649,366,111	**4,975,746,875**	4,212,131,287
Other Income	**252,003,965**	144,386,603	**131,411,312**	79,407,469
Administrative Expenses	**(5,506,397,054)**	(4,593,210,050)	**(2,174,515,305)**	(1,882,728,478)
Selling and Distribution Expenses	**(646,476,582)**	(470,692,088)	**(305,238,862)**	(255,923,338)
Finance Costs	**(1,133,429,003)**	(1,014,698,667)	**(926,949,936)**	(790,281,715)
Finance Income	**1,109,864,157**	409,948,259	**456,392,163**	110,889,742
Profit Before Tax	**4,496,187,909**	3,125,100,168	**2,156,846,247**	1,473,494,966
Tax Expense	**(1,208,455,798)**	(798,681,112)	**(534,478,442)**	(286,341,479)
Profit for the Period	**3,287,732,111**	2,326,419,056	**1,622,367,805**	1,187,153,487
Attributable to:				
Equity Holders of the Parent Company	**3,076,402,231**	2,177,325,041		
Non-Controlling Interest	**211,329,880**	149,094,015		
	3,287,732,111	2,326,419,056		
Earnings Per Share- Basic	**2.70**	1.91	**1.43**	1.04
Dividend Per Share- Ordinary Shares	**0.00**	**0.00**	**0.00**	**0.00**

STATEMENT OF COMPREHENSIVE INCOME

For the Period Ended 30 September 2026

	Group		Company	
	30-Sep-26 Rs. Un-audited	**30-Sep-25 Rs. Un-audited**	**30-Sep-26 Rs. Un-audited**	**30-Sep-25 Rs. Un-audited**
Profit for the Period	**3,287,732,111**	2,326,419,056	**1,622,367,805**	1,187,153,487
Other Comprehensive Income not to be reclassified to Statement of Profit or Loss in subsequent periods:				
Net loss on disposal of subsidiary shares designated at FVTOCI	-	-	**(396,679,848)**	-
Net Other Comprehensive Income not to be reclassified to Statement of Profit or Loss in subsequent periods:	-	-	**(396,679,848)**	-
Other Comprehensive Income to be Reclassified to Statement of Profit or Loss in subsequent periods:				
Net Other Comprehensive Income to be Reclassified to Statement of Profit or Loss in subsequent periods	-	-	-	-
Other Comprehensive Loss for the Period, Net of Tax	-		**(396,679,848)**	
Total Comprehensive Income for the Period, Net of Tax	**3,287,732,111**	2,326,419,056	**1,225,687,957**	1,187,153,487
Total Comprehensive Income Attributable to:				
Equity Holders of the Parent Company	**3,076,402,231**	2,177,325,041		
Non-Controlling Interest	**211,329,880**	149,094,015		
	3,287,732,111	2,326,419,056		

Asiri Hospital Holdings PLC and Its Subsidiaries

STATEMENT OF PROFIT OR LOSS

For the Three Months Ended 30 September 2026

	GROUP		COMPANY	
	30-Sep-26	**30-Sep-25**	**30-Sep-26**	**30-Sep-25**
	Rs.	**Rs.**	**Rs.**	**Rs.**
	Un-audited	**Un-audited**	**Un-audited**	**Un-audited**
Revenue	**10,644,777,742**	8,520,190,303	**4,764,603,660**	3,915,054,716
Cost of Services	**(5,073,820,618)**	(4,309,471,843)	**(2,110,837,787)**	(1,819,461,368)
Gross Profit	**5,570,957,124**	4,210,718,460	**2,653,765,873**	2,095,593,348
Other Income	**179,660,071**	68,159,409	**87,692,642**	35,678,975
Administrative Expenses	**(2,825,221,228)**	(2,346,905,222)	**(1,124,607,720)**	(973,795,715)
Selling and Distribution Expenses	**(337,479,763)**	(238,038,693)	**(159,044,504)**	(130,832,141)
Finance Costs	**(634,168,866)**	(522,068,314)	**(473,140,022)**	(404,723,473)
Finance Income	**643,732,153**	203,427,438	**259,003,221**	55,260,683
Profit Before Tax	**2,597,479,491**	1,375,293,078	**1,243,669,489**	677,181,677
Tax Expense	**(671,951,209)**	(275,180,733)	**(303,614,181)**	(56,214,491)
Profit for the Period	**1,925,528,282**	1,100,112,345	**940,055,308**	620,967,187
Attributable to:				
Equity Holders of the Parent Company	**1,791,784,333**	1,018,989,936		
Non-Controlling Interests	**133,743,949**	81,122,409		
	1,925,528,282	1,100,112,345		
Earnings Per Share - Basic	**1.58**	0.90	**0.83**	0.55
Dividend Per Share - Ordinary Shares	**0.00**	**0.00**	**0.00**	**0.00**

STATEMENT OF COMPREHENSIVE INCOME

For the Three Months Ended 30 September 2026

	Group		Company	
	30-Sep-26 Rs. Un-audited	**30-Sep-25 Rs. Un-audited**	**30-Sep-26 Rs. Un-audited**	**30-Sep-25 Rs. Un-audited**
Profit for the Period	**1,925,528,282**	1,100,112,345	**940,055,308**	620,967,187
Other Comprehensive Income not to be reclassified to Statement of Profit or Loss in subsequent periods:				
Net loss on disposal of subsidiary shares designated at FVTOCI	-	-	(205,033,901)	-
Net Other Comprehensive Income not to be reclassified to Statement of Profit or Loss in subsequent periods	-	-	**(205,033,901)**	-
Other Comprehensive Income to be Reclassified to Statement of Profit or Loss in subsequent periods:				
Net Other Comprehensive Income to be Reclassified to Statement of Profit or Loss in subsequent periods	-	-	-	-
Other Comprehensive Loss for the Period, Net of Tax	-	-	(205,033,901)	-
Total Comprehensive Income for the Period, Net of Tax	**1,925,528,282**	1,100,112,345	**735,021,407**	620,967,187
Attributable to:				
Equity Holders of the Parent Company	**1,791,784,333**	1,018,989,936		
Non-Controlling Interests	**133,743,949**	81,122,409		
	1,925,528,282	1,100,112,345		

Asiri Hospital Holdings PLC and Its Subsidiaries

STATEMENT OF FINANCIAL POSITION

GROUP	COMPANY		GROUP		COMPANY	
31-Mar-26	31-Mar-26		30-Sep-26	30-Sep-25	30-Sep-26	30-Sep-25
Rs.	Rs.		Rs.	Rs.	Rs.	Rs.
Audited	Audited	ASSETS	Un-audited	Un-audited	Un-audited	Un-audited
		Non-current Assets				
36,804,361,018	15,362,378,870	Property, Plant and Equipment	**37,219,575,429**	35,011,911,910	**15,267,686,254**	14,767,410,484
1,485,760,545	1,151,382,413	Right of Use Assets	**1,366,394,799**	1,275,872,743	**1,152,889,999**	992,113,307
609,654,071	-	Goodwill	**609,654,071**	609,654,071	-	-
-	44,029,769,666	Investment in Subsidiaries	-	-	**43,143,740,252**	41,413,070,184
8,494,243,162	1,716,993,998	Loans granted to Related Parties	**11,112,567,945**	7,442,640,344	**1,881,248,562**	-
91,315,924	43,958,548	Other Non Current Assets	**80,006,717**	75,040,643	**54,024,717**	49,058,643
58,281,868	58,281,868	Other Non-Current Financial Assets	**1,062,514,533**	57,200,837	**1,062,514,533**	57,200,837
47,543,616,588	**62,362,765,363**		**51,450,713,494**	44,472,320,550	**62,562,104,318**	57,278,853,456
		Current Assets				
1,389,447,790	612,660,847	Inventories	**1,485,901,073**	1,213,611,912	**645,742,423**	544,067,171
2,046,751,592	2,993,944,289	Trade and Other Receivables	**2,079,227,889**	2,441,388,806	**4,122,329,279**	2,953,080,771
1,005,595,911	845,984,986	Loans Granted to Related Parties	**1,004,944,170**	1,317,069,353	**845,984,986**	1,749,950,415
7,291,145,851	3,415,745,540	Other Current Assets	**11,193,588,744**	8,222,646,594	**5,006,255,389**	2,574,557,455
920,371,972	120,653,845	Cash and Cash Equivalents	**992,869,448**	791,417,544	**198,900,497**	198,742,188
12,653,313,115	**7,988,989,507**		**16,756,531,324**	13,986,134,209	**10,819,212,574**	8,020,398,001
60,196,929,703	**70,351,754,870**	**Total Assets**	**68,207,244,818**	58,458,454,759	**73,381,316,892**	65,299,251,456
		EQUITY AND LIABILITIES				
		Capital and Reserves				
4,748,108,324	4,748,108,334	Stated Capital	**4,748,108,334**	4,748,108,334	**4,748,108,334**	4,748,108,334
12,263,761,541	30,052,065,552	Other Components of Equity	**12,282,199,968**	11,710,995,075	**29,342,474,641**	27,624,699,191
6,724,132,071	2,624,010,687	Retained Earnings	**9,800,534,302**	5,458,129,823	**4,559,289,555**	2,811,980,491
23,736,001,947	**37,424,184,573**	**Share Holders' Fund**	**26,830,842,604**	21,917,233,231	**38,649,872,530**	35,184,788,016
2,112,500,969	-	Non-Controlling Interests	**2,794,741,855**	1,938,366,513	-	-
25,848,502,915	**37,424,184,573**	**Total Equity**	**29,625,584,459**	23,855,599,744	**38,649,872,530**	35,184,788,016
		Non-current Liabilities				
5,798,219,760	8,333,395,093	Interest Bearing Loans and Borrowings	**7,074,287,877**	3,545,493,557	**8,189,020,901**	6,012,115,496
6,112,636,319	9,750,205,249	Deferred Tax Liabilities	**6,353,640,887**	6,197,731,321	**9,965,858,825**	9,317,239,116
1,127,247,506	451,918,687	Employee Benefit Liability	**1,180,772,046**	883,688,607	**472,058,369**	354,426,168
13,038,103,586	**18,535,519,029**		**14,608,700,810**	10,626,913,485	**18,626,938,095**	15,683,780,780
		Current Liabilities				
5,826,909,105	3,827,058,537	Trade and Other Payables	**6,906,880,134**	6,518,497,070	**4,782,524,841**	2,204,936,658
81,387,228	77,784,185	Dividend Payable	**79,618,439**	92,760,502	**76,174,542**	78,447,677
8,192,948,145	6,696,582,567	Interest Bearing Loans and Borrowings	**9,220,479,980**	10,978,271,550	**7,576,850,780**	8,820,743,003
3,044,108,889	1,310,334,119	Income Tax Payable	**3,353,820,144**	1,726,112,262	**1,380,458,984**	422,337,800
4,164,969,835	2,480,291,859	Bank Overdraft	**4,412,160,852**	4,660,300,146	**2,288,497,119**	2,904,217,523
21,310,323,202	**14,392,051,268**		**23,972,959,548**	23,975,941,530	**16,104,506,266**	14,430,682,661
60,196,929,703	**70,351,754,870**	**Total Equity and Liabilities**	**68,207,244,818**	58,458,454,759	**73,381,316,892**	65,299,251,456
		Net Assets Per Share	23.59	19.27	33.98	30.93

The above figures are provisional & subject to audit.
It is certified that the Financial Statements have been prepared in accordance with the requirements of the Companies Act No.7 of 2007.

-sgd-
.....
S L R Piyal
Director Finance

The Board of Directors is responsible for the preparation and presentation of these Financial Statements.
Signed for and on behalf of the Board.

-sgd-
.....
Ashok Pathirage
Chairman / Managing Director

-sgd-
.....
Haresh Kaimal
Director

06 November 2026
Colombo

STATEMENT OF CHANGES IN EQUITY

For the Period Ended 30 September 2026

GROUP

	Equity Attributable to Equity Holders of the Parent							
	Stated Capital	Revaluation Reserve	Other Reserve	Retained Earnings	Fair Value Reserve of Financial Assets at FVOCI	Foreign Currency Translation Reserve	Minority Interest	Total
	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.
Balance as at 01 April 2025	**4,748,108,334**	**11,693,431,117**	**(919,502,000)**	**4,200,306,782**	**19,040,586**	**(1,476,628)**	**1,789,272,498**	**21,529,180,689**
Profit for the Period	-	-	-	2,177,325,041	-		149,094,015	2,326,419,056
Other Comprehensive Income	-	-	-	-	-	-	-	-
Total Comprehensive Income	-	-	-	**2,177,325,041**	-	-	**149,094,015**	**2,326,419,056**
Balance as at 30 September 2025	**4,748,108,334**	**11,693,431,117**	**(919,502,000)**	**6,377,631,823**	**19,040,586**	**(1,476,628)**	**1,938,366,513**	**23,855,599,744**
Balance as at 01 April 2026	**4,748,108,334**	**13,167,140,573**	**(919,524,919)**	**6,724,132,071**	**19,797,308**	**(3,651,421)**	**2,112,500,969**	**25,848,502,915**
Profit for the Period	-	-	-	3,076,402,231	-	-	211,329,880	3,287,732,111
Other Comprehensive Income	-	-	-	-	-	-	-	-
Total Comprehensive Income	-	-	-	**3,076,402,231**	-	-	**211,329,880**	**3,287,732,111**
Acquisition of Non-Controlling Interest	-	-	1,536,187	-	-	-	(31,608,948)	(30,072,761)
Disposal of Interest in Subsidiaries	-	-	16,902,240	-	-	-	502,519,954	519,422,194
Balance as at 30 September 2026	**4,748,108,334**	**13,167,140,573**	**(901,086,492)**	**9,800,534,302**	**19,797,308**	**(3,651,421)**	**2,794,741,855**	**29,625,584,459**

COMPANY

	Stated Capital	Revaluation Reserve	Fair Value Reserve of Financial Assets at FVOCI	Retained Earnings	Total
	Rs.	Rs.	Rs.	Rs.	Rs.
Balance as at 01 April 2025	**4,748,108,334**	**4,502,387,362**	**23,122,311,829**	**1,624,827,003**	**33,997,634,528**
Profit for the Period	-	-	-	1,187,153,487	1,187,153,487
Other Comprehensive Income	-	-	-	-	-
Total Comprehensive Income	-	-	-	1,187,153,487	1,187,153,487
Balance as at 30 September 2025	**4,748,108,334**	**4,502,387,362**	**23,122,311,829**	**2,811,980,491**	**35,184,788,016**
Balance as at 01 April 2026	**4,748,108,334**	**5,097,392,107**	**24,954,673,445**	**2,624,010,687**	**37,424,184,573**
Profit for the Period	-	-	-	1,622,367,805	1,622,367,805
Other Comprehensive Income	-	-	(709,590,911)	312,911,062	(396,679,848)
Total Comprehensive Income	-	-	(709,590,911)	1,935,278,868	1,225,687,957
Balance as at 30 September 2026	**4,748,108,334**	**5,097,392,107**	**24,245,082,534**	**4,559,289,555**	**38,649,872,530**

STATEMENT OF CASH FLOWS

For the Period Ended 30 September

	GROUP		COMPANY	
	30-Sep-26 Rs. Un-audited	30-Sep-25 Rs. Un-audited	30-Sep-26 Rs. Un-audited	30-Sep-25 Rs. Un-audited
Cash Flows from/(used in) Operating Activities				
Profit Before Tax Expense	**4,496,187,909**	3,125,100,168	**2,156,846,247**	1,473,494,966
Adjustments for				
Depreciation	**986,166,962**	915,928,036	**408,577,110**	387,818,621
Amortisation of Leasehold Assets	**126,709,639**	104,116,379	**90,717,092**	69,008,379
Loss/(Gain) on Disposal of Property, Plant and Equipment	**8,129,410**	(493,990)	**8,958,393**	-
Gain on Disposal of Subsidiary	**(3,308,124)**	-	**(3,308,124)**	-
Provision for Bad and Doubtful Debts	**65,429,011**	27,736,641	**6,956,658**	6,803,039
Retirement Benefit Obligation Expense	**119,619,084**	109,900,922	**47,660,741**	43,833,679
Unrealised Foreign Exchange Gain/(Loss)	**(4,714,673)**	5,824,037	**(84,812)**	3,637,384
Dividend Income	**(48,969,350)**	-	**(48,969,350)**	-
Finance Costs	**1,133,429,003**	1,014,698,667	**926,949,936**	790,281,715
Income from Investments	**(1,109,864,157)**	(409,948,259)	**(456,392,163)**	(110,889,742)
Operating Profit Before Working Capital Changes	**5,768,814,715**	4,892,862,602	**3,137,911,728**	2,663,988,041
Changes in Working Capital				
(Increase)/Decrease in Inventories	**(96,453,283)**	(239,365,551)	**(33,081,576)**	(79,096,037)
(Increase)/ Decrease in Other Current Assets	**(3,368,025,527)**	(2,394,066,468)	**(1,316,600,760)**	(473,217,613)
(Increase)/ Decrease in Trade and Other Receivables	**(97,905,308)**	(393,741,185)	**(1,135,341,648)**	(826,548,013)
(Decrease)/Increase in Trade and Other Payables	**1,079,971,029**	794,442,265	**955,466,304**	(298,346,377)
Cash Generated from Operations	**3,286,401,626**	2,660,131,663	**1,608,354,049**	986,780,002
Income Tax Paid	**(661,668,354)**	(434,145,275)	**(248,700,000)**	(10,000,000)
Finance Costs Paid	**(880,110,847)**	(743,075,790)	**(528,666,698)**	(366,070,739)
Retirement Benefit Payments	**(65,466,528)**	(94,490,511)	**(27,521,059)**	(50,476,638)
Net Cash Generated from Operating Activities	**1,679,155,896**	1,388,420,087	**803,466,292**	560,232,624
Cash Flows from/(used in) Investing Activities				
Purchase of Property, Plant and Equipment	**(1,465,376,898)**	(668,575,324)	**(354,808,237)**	(185,585,320)
Acquisition of Right-of-Use Assets	**(2,413,186)**	(1,464,894)	**(1,902,545)**	(1,464,894)
Net Proceeds from Acquisition and Disposal of Investments in Subsidiaries	**3,308,125**	-	**492,657,558**	(27,655)
Increase in investment in shares	**(1,004,232,665)**	-	**(1,004,232,665)**	-
Increase in Loans Granted to Related Parties	**(2,035,000,000)**	-	**-**	-
Proceeds from/(Repayment of) Loans from Related Parties	**(61,068,347)**	120,000,000	**-**	-
Dividends Received	**48,969,350**	-	**48,969,350**	-
Proceeds from Disposal of Property, Plant and Equipment	**32,301,890**	2,965,305	**31,965,328**	1,605,164
Investment Income Received	**2,294,268**	2,069,323	**342,309**	382,946
Net Cash used in Investing Activities	**(4,481,217,464)**	(545,005,590)	**(787,008,901)**	(185,089,758)
Cash Flows from/(used in) Financing Activities				
Dividends (Paid)/Reversal of Unclaimed Dividends	**(1,768,789)**	16,999,281	**(1,609,643)**	16,999,281
Net Cash Flows from Acquisition and Disposal of Non-Controlling Interests in Subsidiaries	**489,349,433**	(27,655)	**-**	-
Net Proceeds from/(Repayments of) External Borrowings	**2,296,984,940**	(979,084,372)	**372,039,485**	(232,909,007)
Repayment of Lease Liabilities	**(157,197,556)**	(128,359,766)	**(116,845,842)**	(87,566,141)
Net Cash from/(used in) Financing Activities	**2,627,368,027**	(1,090,472,511)	**253,584,000**	(303,475,867)
Net Increase/(Decrease) in Cash and Cash Equivalents	**(174,693,541)**	(247,058,015)	**270,041,391**	71,666,999
Cash and Cash Equivalents at the Beginning of the Year	**(3,244,597,863)**	(3,621,824,586)	**(2,359,638,014)**	(2,777,142,338)
Cash and Cash Equivalents at the End of the Period	**(3,419,291,404)**	(3,868,882,602)	**(2,089,596,623)**	(2,705,475,335)
Analysis of Cash and Cash Equivalents				
Favorable Balances				
Cash in Hand and at Bank	**992,869,448**	791,417,544	**198,900,497**	198,742,188
Unfavorable Balances				
Bank Overdrafts	**(4,412,160,852)**	(4,660,300,146)	**(2,288,497,119)**	(2,904,217,523)
Cash and Cash Equivalents	**(3,419,291,404)**	(3,868,882,602)	**(2,089,596,623)**	(2,705,475,335)

NOTES TO THE INTERIM FINANCIAL STATEMENTS

For the Period Ended 30 September 2026

1. Corporate Information

1.1 General

Asiri Hospital Holdings PLC ("Company") is a public limited liability Company, incorporated and domiciled in Sri Lanka and listed on the Colombo Stock Exchange. The registered office and principal place of business is located at No. 181, Kirula Road, Colombo 5.

1.2 Date of Authorisation for Issue

The Interim Condensed Financial Statements of the Group and the Company for the period ended 30 September 2026 were authorised for issue by the Board of Directors on 06 November 2026.

2. Basis of Preparation

The Interim Condensed Financial Statements have been prepared in accordance with Sri Lanka Accounting Standard - LKAS 34 Interim Financial Reporting. These interim condensed financial statements should be read in conjunction with the annual financial statements for the year ended 31 March 2026. These financial statements provide the information as required in terms of Rule 7.4 of the Colombo Stock Exchange.

3. Accounting Policies

The same accounting policies and methods of computation as stated in the annual financial statements for the year ended 31 March 2026 are followed in the preparation of these Interim Condensed Financial Statements.

4. Other Information

4.1 Loans Granted to Related Parties

Group

This includes loans granted to Softlogic Holdings PLC, Softlogic Brands (Pvt) Ltd ,Softlogic Super market (Pvt) Ltd, ODEL PLC,Softlogic Retail (Pvt) Ltd, Softlogic Communication Services (Pvt) Ltd and interest receivable thereon. The interest is charged at prevailing market interest rates for these loans.

Company

This includes loans granted to Softlogic Holdings PLC, ODEL PLC, Softlogic Brands (Pvt) Ltd and Softlogic Super Market (Pvt) Ltd and interest receivable thereon. The interest is charged at prevailing market interest rates for these loans.

4.2 Other Current Assets

Group

Other Current Assets include advances granted to related parties in the ordinary course of the Group's financial and treasury operations, amounting to Rs.10,509,514,630 as at 30 September 2026 (30 September 2025: Rs. 4,778,172,946 ; 31 March 2026: Rs. 7,291,145,851).

4.3 Contingent Liabilities

A dispute has arisen with the Department of Inland Revenue with regard to the applicability of the income tax exemption for the years of assessment 2005/06 to 2014/15, in terms of the agreement entered between Asiri Surgical Hospital PLC and the Board of Investment of Sri Lanka (BOI) in 2000. With respect to the same we have received written notifications from the Tax Appeals Commission so far for the years of assessments 2005/06, 2006/07, 2007/08, 2008/09, 2009/10, 2010/11, 2011/12, 2012/13, 2013/14 and 2014/15 and the Tax payable on the same is Rs. 1.2Bn including penalty of which Rs. 591Mn was provided at 30th September 2026.

We also had filed a case in the Court of Appeal preventing the recoverability of tax for the same matter and appeal is made to the Supreme Court. Since there is a litigation, in accordance with Paragraph 92 of LKAS 37, we are unable to provide further information on this and associated risks, in order not to impair the outcome and/or prejudice the Company's position in this matter.

Other than above, there are no significant changes in the nature of the contingent liabilities and contingent assets which were disclosed in the Annual Report for the year ended 31 March 2026.

4.4 Capital Expenditure Commitments

There were no material commitments outstanding as at 30 September 2026 for future capital expenditure.

4.5 Comparative Information

Where necessary comparative figures have been reclassified to conform with the current year's presentation.

4.6 Events Occurring After the Reporting Period

There were no material events that occurred after the reporting date that require adjustments or disclosure to the Financial Statements.

NOTES TO THE INTERIM FINANCIAL STATEMENTS
For the Period Ended 30 September 2026

Segment Information

The Senior Management Committee acts as the Chief Operating Decision Maker (CODM) and reviews the operating results of the Group's business units separately to support decisions on resource allocation and performance evaluation. Segment performance is assessed based on revenue and other income generated, measured on a basis consistent with the amounts reported in the Consolidated Financial Statements.

Based on the information presented to the CODM for these purposes, the Group has identified its reportable segments accordingly for the interim period.

- Pre Care which include OPD revenue, channeling revenue and OPD lab investigation services
- Post Care which include all IPD revenue including inpatient drugs and lab investigation
- Pharmaceutical which includes Pharmacy revenue
- Other revenue includes income generated from healthcare professional services provided by Asiri Academy of Health Sciences (Pvt) Ltd.

Segment	Group		Company	
	2026	2025	2026	2025
	Rs.	Rs.	Rs.	Rs.
Pre Care	10,326,135,262	9,122,904,521	6,673,893,560	5,874,616,143
Post Care	8,451,340,160	6,931,406,811	1,879,864,008	1,534,635,218
Pharmaceutical	1,344,080,286	1,151,396,816	453,100,280	439,743,480
Other services	39,262,818	34,752,789	-	-
	20,160,818,528	17,240,460,935	9,006,857,848	7,848,994,841

INVESTOR INFORMATION

Market Value of Shares

The market value of an ordinary share of Asiri Hospital Holdings PLC is as follows:

	Quarter to 30-Sep-26	Quarter to 30-Sep-25
Highest Price per Share (Rs.)	38.40	41.00
Lowest Price per Share (Rs.)	27.70	31.00
Last Traded Price per Share (Rs.)	28.00	36.80

No of Shares Representing Stated Capital	As at 30-Sep-26	As at 30-Sep-25
No of Ordinary Shares	1,137,533,596	1,137,533,596

* Earnings and net assets per share are based on 1,137,533,596 shares in issue as at 30 september 2026.

Statement of Shareholding of Directors Name of Director	As at 30-Sep-26	As at 30-Sep-25
Mr. A. K. Pathirage	371,664	371,664
Mr. Rajaratnam Selvaskadan	-	-
Mr. Vishal Bali	-	-
Mr. A. N. Thadani	-	-
Mr. H K Kaimal	-	-
Mr. Govinda Waduge Don Hemantha Udaya Gunawardena	-	-
Mr. Saar Shapira	-	-
Mr. M.I. Furkan	-	-
Mr. Galle Dodanduwage Kalum Lakmal De Silva	-	-

Major Shareholdings Twenty Largest Shareholders	As at 30-Sep-26	%	As at 30-Sep-25	%
Softlogic Holdings PLC	623,709,098	54.83	627,025,050	55.12
Merrill Lynch Pierce Fenner & Smith-Tpg Growth Iii Sf Pte Ltd	328,258,328	28.86	328,258,328	28.86
BBH-Tundra Sustainable Frontier Fund	30,000,000	2.64	30,000,000	2.64
Softlogic Life Insurance Plc-A/C No. 04 (Participating Fund)	9,000,000	0.79	9,000,000	0.79
Sri Lanka Insurance Corporation Ltd-Life Fund	7,851,792	0.69	7,851,79	0.69
Mr. Pujitha Punsiri Subasinghe	7,420,340	0.65	7,385,340	0.65
Softlogic Life Insurance Plc-A/C No. 05 (Non-Participating Fund)	5,956,877	0.52	5,956,877	0.52
Deutsche Bank Ag As Trustee For Jb Vantage Value Equity Fund	3,865,099	0.34	5,090,006	0.45
Jafferjee Brothers Exports (Private)Limited	3,616,000	0.32	3,487,500	0.31
Dr. Welagedara Mudiyanselage Swarnamali Welagedara	3,375,000	0.30	3,375,000	0.30
J.B. Cocoshell (Pvt) Ltd	2,907,958	0.26	7,488,264	0.66
Mr. Hewa Komanage Jayantha Dharmadasa	2,826,650	0.25	2,908,650	0.26
Dr. Luhubanduwaduge Don Abo Claudius Luvis	2,557,423	0.22	2,557,423	0.22
Employees Trust Fund Board	2,337,161	0.21	4,245,693	0.37
Mr. Mohamed Faizer Hashim	2,087,160	0.18	2,087,160	0.18
Miss Theja Thushari Weerasinghe	1,746,630	0.15	1,746,630	0.15
Commercial Bank of Ceylon PLC	1,646,186	0.14	-	-
Sri Lanka Insurance Corporation Ltd-General Fund	1,557,417	0.14	1,557,417	0.14
Mr. Vigneswaramoorthy Sunilgavasker	1,511,460	0.13	-	-
Mr. Uditha Harilal Palihakkara	1,505,825	0.13	1,436,255	0.13
	1,043,736,404	91.75	1,043,605,593	91.74
Shares held by the Balance Shareholdings	93,797,192	8.25	93,928,003	8.26
Total Issued Shares	1,137,533,596	100.00	1,137,533,596	100.00
Public Shareholding	170,237,629	14.97	166,921,677	14.67
Total Number of Public Shareholders	7,233		5,761	

The Float- adjusted market capitalization as at 30th September 2026 is Rs. 478,511,469,892.57 and the Company is in compliance with option 3 of the CSE Listing Rules 7.13.1 (i) (a) which requires 7.5 % minimum public holding percentage and 500 minimum public shareholders.

CORPORATE INFORMATION

Name of the Company
Asiri Hospital Holdings PLC

Registered Office
181, Kirula Road, Colombo 05,
Sri Lanka.

Office & Administrative Complex
Asiri Surgical Hospital PLC
21, Kirimandala Mawatha,
Colombo 05, Sri Lanka.
Telephone: 011 4524400
Email: info@asiri.lk
Web: www.asirihealth.com

Company Registration Number
PQ204

Legal Form
A quoted public company incorporated in Sri Lanka on 29 September 1980, under the Companies Act No.17 of 1982, with limited liability.Re-registered on 30 September 2008 under the Companies Act No. 07 of 2007.

Stock Exchange Listing
The Ordinary Shares of the Company have been listed with the Colombo Stock Exchange since June 1986.

Board of Directors
Mr. A. K. Pathirage - Chairman/Managing Director
Mr. G. W.D.H. U. Gunawardena
Mr. Rajaratnam Selvaskandan
Mr. H K Kaimal
Mr.V. Bali
Mr. A. N. Thadani
Mr. S. Shapira
Mr. M.I. Furkan
Mr. G.D.K.L.De Silva

Audit Committee
Chairman
Mr. M.I. Furkan
Independent Non- Executive Director

Committee Members
Mr. G.D.K.L.De Silva
Independent Non-Executive Director

Mr. H K Kaimal
Non Independent Non-Executive Director

Frequency of Meetings
Committee meets quarterly

Nomination and Governance Committee
Chairman
Mr. M.I. Furkan
Independent Non- Executive Director

Committee Members
Mr. G.D.K.L.De Silva
Independent Non-Executive Director

Mr.V. Bali
Independent Non-Executive Director

Frequency of Meetings
Committee meets once each year or as required.

Related Party Transactions Review Committee
Chairman
Mr. M.I. Furkan
Independent Non- Executive Director

Committee Members
Mr. G.D.K.L.De Silva
Independent Non-Executive Director

Mr. H K Kaimal
Non Independent Non-Executive Director

Frequency of Meetings
Committee meets quarterly

Subsidiary Companies
Central Hospital Ltd
114, Norris Canal Road, Colombo 10.

Asiri Central Hospitals Ltd
114, Norris Canal Road, Colombo 10.

Asiri Surgical Hospital PLC
21, Kirimandala Mawatha, Colombo 5.

Asiri Diagnostics Services (Pvt) Ltd
181, Kirula Road, Colombo 05.

Asiri Hospital Matara (Pvt) Ltd
26, Esplanade Road, Uyanwatte,
Matara.

Asiri Laboratories (Pvt) Ltd
181, Kirula Road, Colombo 5.

Asiri Hospital Galle (Pvt) Ltd
10, Wackwella Road, Galle.

Asiri AOI Cancer Centre (Pvt) Ltd
21, Kirimandala Mawatha, Colombo 5.

Asiri Port City Hospital (Pvt) Ltd.
14, De Fonseka Place, Colombo 5.

Asiri Diagnostics Services (Asia) Pte Limited
8, Temasek Boulevard, # 35-03 Suntec Tower 3.
Singapore.

Auditors
Messrs. Ernst & Young
(Chartered Accountants)
109, Galle Road,
Colombo 03.

Secretaries
Messrs. Softlogic Corporate Services (Pvt) Ltd
14, De Fonseka Place, Colombo 5.

Stock Code
ASIR.N0000

Bankers
Commercial Bank of Ceylon PLC
Sampath Bank PLC
Nations Trust Bank PLC
Hatton National Bank PLC
Cargills Bank Limited
Bank of Ceylon PLC
National Development Bank PLC
Seylan Bank PLC
DFCC Bank PLC
Union Bank of Colombo PLC